Combivent UDV

Combivent UDV

ipratropium bromide + salbutamol

Manufacturer:

Boehringer Ingelheim

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Ipratropium Br 0.5 mg, salbutamol 2.5 mg
Indications/Uses
Management of reversible bronchospasm associated w/ obstructive pulmonary disease in patients who require more than single bronchodilator.
Dosage/Direction for Use
Adult (including elderly) & childn >12 yr Acute attacks 1 unit dose vial. Administer 2nd unit dose vial in severe cases. Maintenance: 1 unit dose vial tid-qid.
Contraindications
Hypersensitivity to atropine or its derivatives. Hypertrophic obstructive cardiomyopathy, tachyarrhythmia.
Special Precautions
Discontinue immediately if paradoxical bronchospasm occurs. Immediate hypersensitivity reactions. Patients predisposed to glaucoma; ocular complications ie, mydriasis, increased IOP, narrow-angle glaucoma, eye pain. Insufficiently controlled DM, recent MI, severe organic heart or vascular disorders, hyperthyroidism, phaeochromocytoma, risk of narrow-angle glaucoma, prostatic hypertrophy or bladder-neck obstruction. Potentially serious hypokalaemia. Chest pain or other symptoms of worsening heart disease; acute, rapidly worsening dyspnoea. Patients w/ cystic fibrosis may be more prone to GI motility disturbances; underlying severe heart disease eg, ischaemic heart disease, tacchyarrhythmia or severe heart failure. May lead to +ve results in doping tests. Monitor serum K levels. May affect ability to drive or use machines. Hepatic or renal impairment. Pregnancy & lactation. Not indicated for ped patient.
Adverse Reactions
Headache, throat irritation, cough, dry mouth, GI motility disorders (eg, constipation, diarrhea, vomiting), nausea & dizziness.
Drug Interactions
Increased side effects w/ xanthine derivatives. Not recommended w/ other anticholinergics. Increased hypokalaemia w/ xanthine derivatives, glucocorticoids, diuretics. Increased susceptibility to arrhythmias w/ digoxin. Reduced effect w/ β-blockers. Enhanced effects w/ MAOIs & TCAs. Increased susceptibility to CV effects w/ halogenated hydrocarbon anaesth eg, halothane, trichloroethylene & enflurane.
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03AL02 - salbutamol and ipratropium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Combivent UDV inhalation soln
Packing/Price
(unit dose) 2.5 mL x 60 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in